Australia-based biotechnology company Progen Pharmaceuticals has discontinued the PI-88 Phase III study in liver cancer. The company said that the trial is unlikely to meet the forecast patient recruitment timetable and further significant delays were expected due to - slower than expected regulatory processes in China, Korea and Vietnam; slower than expected initiation of clinical sites; slower than expected recruitment of patients into active sites; and the recent launch of a competitive Phase III trial, assessing Bayer/Onyx Nexavar in the same indication. As part of the strategic review, Progen has determined that the current Phase IIb melanoma trial, will be completed but no further development in melanoma by Progen is anticipated at this stage. This trial is expected be finalized at an estimated additional cost of...
[read full story]
Your Web Site
